Skye Bioscience Balance Sheet Health
Financial Health criteria checks 6/6
Skye Bioscience has a total shareholder equity of $78.9M and total debt of $4.6M, which brings its debt-to-equity ratio to 5.8%. Its total assets and total liabilities are $94.8M and $16.0M respectively.
Key information
5.8%
Debt to equity ratio
US$4.61m
Debt
Interest coverage ratio | n/a |
Cash | US$83.47m |
Equity | US$78.88m |
Total liabilities | US$15.95m |
Total assets | US$94.84m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: SKYE's short term assets ($94.6M) exceed its short term liabilities ($15.8M).
Long Term Liabilities: SKYE's short term assets ($94.6M) exceed its long term liabilities ($151.0K).
Debt to Equity History and Analysis
Debt Level: SKYE has more cash than its total debt.
Reducing Debt: SKYE had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SKYE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SKYE has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 23.8% each year.